Randomized Trial of Specialty Palliative Care Integrated with Critical Care for Clinically Ill Older Adults at High Risk of Death or Severe Disability - Supplement
针对死亡或严重残疾高风险的临床疾病老年人的专业姑息治疗与重症监护相结合的随机试验 - 补充
基本信息
- 批准号:10714105
- 负责人:
- 金额:$ 39.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-15 至 2023-12-31
- 项目状态:已结题
- 来源:
- 关键词:AcademyAcuteAdministrative SupplementAlzheimer&aposs disease patientAlzheimer&aposs disease related dementiaAreaCaregiver supportCaregiversCaringCommunicationComplexCritical CareCritical IllnessDataElderlyEnhancement TechnologyFamilyFamily CaregiverGoalsGroup ProcessesHealthHospitalizationHospitalsInterventionLightMedicineMethodsOutcomePalliative CareParentsPatient CarePatient PreferencesPatient-Centered CarePatientsPhysiciansProviderQuality of CareResearch PersonnelSignal TransductionSpecialistTechnologyTraining ProgramsTreatment EfficacyWorkarmclinical caredisabilityefficacy evaluationend of lifeevidence basefunctional declinehigh riskhospital readmissionimprovedinnovationmedical specialtiesmortality riskolder patientpatient engagementpilot trialprogramsrandomized trialskill acquisitionskillsusability
项目摘要
ABSTRACT
The National Academy of Medicine has identified improving clinicians’ serious illness
communication skills (SICS) as a priority area to improve patient and family outcomes near the end
of life. SICS are particularly important for hospitalized patients with moderate-to-severe Alzheimer’s
disease or related dementias (ADRD) because: 1) patients’ preferences vary substantially regarding
goals of care in this context; and 2) hospitalization often signals a worsening health trajectory with
cascading readmissions and functional decline, and therefore presents an opportunity to engage in
robust goals of care conversations. However, a critical barrier to achieving widespread
improvements in this aspect of care for hospitalized ADRD patients is the absence of a scalable,
empirically-validated way to help clinicians acquire the complex communication skills needed to
engage patients and families in goals of care discussions in the hospital setting.
The parent R01 on which this supplement builds is an RCT among critically ill older patients
assessing the efficacy of an intervention involving goals-of-care conversations delivered by palliative
care (PC) specialists to improve patient and family caregiver outcomes. The broad focus of both the
parent R01 and this ADRD supplement is on caregiver support and patient-centered care through
enhanced clinician-patient-caregiver communication. In light of the workforce shortages for PC
specialists, improving the skills of non-PC specialists, which is the goal of the supplement proposal,
is a critical strategy to increase care quality for hospitalized ADRD patients.
Our goal is to create and disseminate a technology-enhanced intervention that is both
scalable and empirically-validated to help hospital-based physicians and advanced practice
providers (APPs) acquire the skills needed to effectively conduct goals-of-care conversations for
hospitalized patients with ADRD and their families. Therefore, in Aim 1, we will use a nominal group
process to engage a diverse stakeholder panel in the construction of the technology-enhanced SICS
intervention for clinicians treating patients with ADRD. In Aim 2, we will conduct a single-arm pilot
trial to evaluate the feasibility, acceptability, and efficacy (i.e., skills acquisition) of the SICS
intervention.
The proposed work will have high impact because it will yield the preliminary data needed
for a successful R01 application to conduct an RCT to determine the impact of the scalable SICS
intervention on the outcomes of hospitalized patients with ADRD and their caregivers. The project is
innovative because it seeks to develop the first empirically-validated SICS intervention for clinicians
of patients with ADRD that leverages technology to achieve high scalability. The work is feasible in
our hands because we are a team of established investigators with a strong commitment to
improving patient and caregiver outcomes in ADRD.
摘要
美国国家医学院已确定改善临床医生的严重疾病
沟通技巧(SICS)作为一个优先领域,以改善病人和家庭的结果接近尾声
生命SICS对于患有中度至重度阿尔茨海默病的住院患者尤为重要
疾病或相关痴呆症(ADRD),因为:1)患者的偏好差异很大,
在这种情况下的护理目标;和2)住院治疗往往标志着健康轨迹恶化,
级联再入院和功能下降,因此提供了一个机会,
护理对话的强大目标。然而,实现广泛传播的一个关键障碍
在对住院ADRD患者的护理方面的改进是缺乏可扩展的,
经过临床验证的方法,帮助临床医生获得所需的复杂沟通技能,
让病人和家属参与医院环境中的护理目标讨论。
本补充材料所基于的母体R 01是一项在危重老年患者中开展的RCT
评估干预的有效性,包括姑息治疗提供的护理目标对话,
护理(PC)专家,以改善患者和家庭护理人员的结果。两者的广泛焦点
父母R 01和本ADRD补充是关于照顾者支持和以病人为中心的护理,通过
加强临床医生-患者-护理人员的沟通。鉴于PC的劳动力短缺
专家,提高非PC专家的技能,这是补充建议的目标,
是提高住院ADRD患者护理质量的关键策略。
我们的目标是创造和传播一种技术增强的干预措施,
可扩展且经过医学验证,可帮助医院医生和高级实践
提供者(APP)获得有效进行护理目标对话所需的技能,
ADRD住院患者及其家属。因此,在目标1中,我们将使用一个名义组
在技术增强型SICS的建设过程中,
治疗ADRD患者的临床医生的干预。在目标2中,我们将进行单臂试验
评估可行性、可接受性和有效性的试验(即,技能获取)
干预
拟议的工作将产生很大的影响,因为它将产生所需的初步数据
对于成功的R 01应用程序,执行RCT以确定可扩展SICS的影响
干预对ADRD住院患者及其照顾者结局的影响。该项目
创新,因为它旨在为临床医生开发第一个经过验证的SICS干预措施
利用技术实现高度可扩展性的ADRD患者。这项工作在
我们的手,因为我们是一个团队的建立调查与坚定的承诺,
改善ADRD患者和护理人员的结局。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yael Schenker其他文献
Yael Schenker的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yael Schenker', 18)}}的其他基金
Midcareer Investigator Award in Patient-Oriented Research: Yael Schenker, MD, MAS
以患者为导向的研究中的职业生涯中期研究员奖:Yael Schenker,医学博士,MAS
- 批准号:
10390440 - 财政年份:2021
- 资助金额:
$ 39.45万 - 项目类别:
Midcareer Investigator Award in Patient-Oriented Research: Yael Schenker, MD, MAS
以患者为导向的研究中的职业生涯中期研究员奖:Yael Schenker,医学博士,MAS
- 批准号:
10592288 - 财政年份:2021
- 资助金额:
$ 39.45万 - 项目类别:
Randomized Trial of Specialty Palliative Care Integrated with Critical Care for Critically Ill Older Adults at High Risk of Death or Severe Disability
针对死亡或严重残疾风险高的危重老年人的专业姑息治疗与重症监护相结合的随机试验
- 批准号:
10663861 - 财政年份:2020
- 资助金额:
$ 39.45万 - 项目类别:
Randomized Trial of Specialty Palliative Care Integrated with Critical Care for Critically Ill Older Adults at High Risk of Death or Severe Disability
针对死亡或严重残疾风险高的危重老年人的专业姑息治疗与重症监护相结合的随机试验
- 批准号:
10256820 - 财政年份:2020
- 资助金额:
$ 39.45万 - 项目类别:
Randomized Trial of Specialty Palliative Care Integrated with Critical Care for Critically Ill Older Adults at High Risk of Death or Severe Disability
针对死亡或严重残疾风险高的危重老年人的专业姑息治疗与重症监护相结合的随机试验
- 批准号:
10437935 - 财政年份:2020
- 资助金额:
$ 39.45万 - 项目类别:
Randomized Trial of Specialty Palliative Care Integrated with Critical Care for Critically Ill Older Adults at High Risk of Death or Severe Disability
针对死亡或严重残疾风险高的危重老年人的专业姑息治疗与重症监护相结合的随机试验
- 批准号:
10030184 - 财政年份:2020
- 资助金额:
$ 39.45万 - 项目类别:
Patient-centered and efficacious advance care planning in cancer: the PEACe comparative effectiveness trial
以患者为中心且有效的癌症预先护理计划:PEACe 比较有效性试验
- 批准号:
10401346 - 财政年份:2019
- 资助金额:
$ 39.45万 - 项目类别:
Patient-centered and efficacious advance care planning in cancer: the PEACe comparative effectiveness trial
以患者为中心且有效的癌症预先护理计划:PEACe 比较有效性试验
- 批准号:
10569584 - 财政年份:2019
- 资助金额:
$ 39.45万 - 项目类别:
A cluster randomized trial of a primary palliative care intervention (CONNECT) for patients with advanced cancer
针对晚期癌症患者进行初级姑息治疗干预 (CONNECT) 的整群随机试验
- 批准号:
9103638 - 财政年份:2016
- 资助金额:
$ 39.45万 - 项目类别:
A cluster randomized trial of a primary palliative care intervention (CONNECT) for patients with advanced cancer
针对晚期癌症患者进行初级姑息治疗干预 (CONNECT) 的整群随机试验
- 批准号:
9268708 - 财政年份:2016
- 资助金额:
$ 39.45万 - 项目类别:
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 39.45万 - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 39.45万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 39.45万 - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 39.45万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 39.45万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 39.45万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 39.45万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 39.45万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 39.45万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
- 批准号:
2244994 - 财政年份:2023
- 资助金额:
$ 39.45万 - 项目类别:
Standard Grant














{{item.name}}会员




